Strategies towards in vivo imaging of active transglutaminase type 2 using positron emission tomography

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Scopus)


Transglutaminase type 2 (TG2) is increasingly linked to the pathogenesis of several diseases, such as celiac disease, cancer, and fibrotic and neurodegenerative diseases. In parallel with becoming an attractive target for therapy, interest in the development of compounds for in vivo imaging of TG2 is rising. Such imaging biomarkers might assist in clarifying the role of TG2 in pathology and in monitoring TG2 inhibition in vivo and thus assist in drug development. In this review, the latest results together with various strategies in TG2 PET tracer development are discussed, including radiolabelling of irreversible and reversible active-site inhibitors, as well as allosteric inhibitors, acyl-donor and acyl-acceptor substrates, and anti-TG2 monoclonal antibodies.

Original languageEnglish
Pages (from-to)585-595
Number of pages11
JournalAmino acids
Issue number3
Publication statusPublished - 1 Mar 2017


  • Antibodies
  • Irreversible TG2 inhibitors
  • PET
  • Reversible TG2 inhibitors
  • Substrates
  • Transglutaminase type 2

Cite this